| __timestamp | Arrowhead Pharmaceuticals, Inc. | Celldex Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 24419536 | 20622000 |
| Thursday, January 1, 2015 | 34718089 | 33837000 |
| Friday, January 1, 2016 | 40998209 | 35979000 |
| Sunday, January 1, 2017 | 32022880 | 25003000 |
| Monday, January 1, 2018 | 19110051 | 19269000 |
| Tuesday, January 1, 2019 | 26556257 | 15426000 |
| Wednesday, January 1, 2020 | 52275890 | 14456000 |
| Friday, January 1, 2021 | 80981000 | 20488000 |
| Saturday, January 1, 2022 | 124431000 | 27195000 |
| Sunday, January 1, 2023 | 90932000 | 30914000 |
| Monday, January 1, 2024 | 98761000 |
Unleashing the power of data
In the competitive world of biotechnology, managing expenses is crucial for sustaining growth and innovation. Arrowhead Pharmaceuticals, Inc. and Celldex Therapeutics, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Arrowhead's SG&A expenses surged by approximately 300%, peaking in 2022. This reflects their aggressive expansion and investment in research and development. In contrast, Celldex's expenses remained relatively stable, with a modest increase of about 50% over the same period. Notably, data for 2024 is missing for Celldex, indicating potential reporting delays or strategic shifts. These trends highlight the differing strategies of these companies in navigating the biotech landscape. As Arrowhead continues to invest heavily, Celldex's steadier approach may suggest a focus on optimizing existing operations.
Cost Management Insights: SG&A Expenses for Novo Nordisk A/S and Celldex Therapeutics, Inc.
Selling, General, and Administrative Costs: Vertex Pharmaceuticals Incorporated vs Celldex Therapeutics, Inc.
Selling, General, and Administrative Costs: BeiGene, Ltd. vs Arrowhead Pharmaceuticals, Inc.
Viatris Inc. or Arrowhead Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Dr. Reddy's Laboratories Limited and Celldex Therapeutics, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Corcept Therapeutics Incorporated vs Arrowhead Pharmaceuticals, Inc.
Comparing SG&A Expenses: ADMA Biologics, Inc. vs Celldex Therapeutics, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? PTC Therapeutics, Inc. or Celldex Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of HUTCHMED (China) Limited and Arrowhead Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Arrowhead Pharmaceuticals, Inc. and MannKind Corporation
Who Optimizes SG&A Costs Better? Wave Life Sciences Ltd. or Celldex Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Dynavax Technologies Corporation and Celldex Therapeutics, Inc.